A new study found that a simple web tool helped patients stay on antidepressants longer than standard prescriptions.
As a result, doctors now have a practical way to reduce early withdrawal and keep patients on treatment long enough to feel safe.
Improving initial decisions
An international trial of 520 adults in 47 clinics in Brazil, Canada and the UK put pressure on initial prescribing.
At the University of Oxford in the UK, Andrea Cipriani, MD, has shown that short digital conversations transform initial follow-through.
Patients guided by a web tool called PETRUSHKA stopped treatment less frequently during the first eight weeks of treatment.
The system helps doctors and patients match antidepressants to individual needs before early side effects and frustration drive people to quit smoking.
Early endurance is important because antidepressants often take several weeks before patients and doctors can determine their effectiveness or adjust treatment strategies.
Struggles in early treatment
Quitting smoking early often results in a mismatch between the effectiveness of the drug and what the patient can tolerate in the first few days.
UK treatment guidance requires clinicians to weigh an individual’s needs, preferences and values during treatment.
“Mental health has lagged behind other medical fields, and for too long antidepressant treatment has relied on trial and error,” Cipriani said.
Petrushka has stepped into that gap by making prioritization a visible part of prescribing decisions.
How Petrushka works
Rather than treating depression as one-size-fits-all, Dr. Petrushka combined age, symptoms, medical details, and treatment preferences.
Behind the screen, artificial intelligence helped rank antidepressants for each person. Patient preferences, especially concerns about side effects that could make daily life difficult, were of great importance.
Ranked lists did not replace doctors. This gave us a clearer starting point, rather than rushing to guess what our plans would be.
Evaluate early success
In the final analysis, 493 adults with major depressive disorder served as the primary comparison.
Within the first two months, fewer patients using Petrushka stopped taking antidepressants than those receiving standard treatment.
This early difference is important because during the first few weeks of treatment, side effects, frustration, or uncertainty often force treatment discontinuation.
While strong numbers do not automatically dictate choice, they do show that personalization has changed treatment decisions in ways that patients and physicians can judge within routine care.
Losing ground due to side effects
The most powerful daily victory came when fewer people stopped taking the drug after starting it because they found it difficult to continue.
Within the first two months, the number of people who stopped using Petrushka because the drug was intolerable or interfered with daily life decreased.
Patients receiving standard treatment were more likely to discontinue treatment because side effects made it difficult to continue treatment.
Symptoms continued to improve
This pattern suggests that the tool has enabled more patients to take antidepressants that they can tolerate until treatment begins to take effect.
After several months, patients using Petrushka still reported fewer symptoms of depression and anxiety than those taking the standard regimen.
Many participants in the tool group stated that by the 6-month follow-up, the impact on their sleep, concentration, motivation, and daily life had been reduced.
The findings of this study suggest that early selection of a more appropriate antidepressant may shape the evolution of treatment beyond the initial prescription.
Adaptation to primary care
Practical design is important because the best prescription aids will not work if busy clinics cannot readily use them during short consultations.
PETRUSHKA was implemented as a web application that clinicians could open on their computers, smartphones, and tablets.
Used together by clinicians and patients, evidence and personal preferences were met before a prescription was selected. In primary care, shared screens are likely to be most important.
The patient’s voice was heard
Patient participation before testing shaped the tool, allowing the project to keep the focus on fears that are often left unspoken.
People with depression and their caregivers collaborated on Petrushka to connect antidepressant choice to lived experience.
“Petrushka found a much milder drug than anything I had taken before,” said Henry Winchester, a freelance writer and trial participant from Bristol, England.
His explanation shows why personalization needs to include tolerability, not just symptom targeting.
Limits still matter
Trial restrictions ensure that results are not a blank test for all clinics and all patients. Patients and clinicians know whether they have used Petrushka, which may influence expectations and follow-up actions.
Missing follow-up information also limited the scope for subsequent comparisons, especially during the 24-week follow-up when fewer people had complete data.
Even with these limitations, the early stopping difference provides a clear target to test in future trials without overselling certainty.
What will change next?
Improving the suitability of antidepressants could save appointments, reduce frustration, and allow more patients to reach a point where treatment is effective.
Next steps should test long-term outcomes and costs and utilize external research settings in clinics with fewer mental health professionals.
This research Japan Automobile Manufacturers Association.
—–
Like what you read? Subscribe to our newsletter for fascinating articles, exclusive content and the latest updates.
Check out EarthSnap, a free app from Eric Ralls and Earth.com.
—–
